BRAFV600E mutation correlates with suppressive tumor immune microenvironment and reduced disease-free survival in Langerhans cell histiocytosis

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

(2015) David M. Hyman et al.   NEW ENGLAND JOURNAL OF MEDICINE

FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor

(2015) Connull Leslie et al.   PATHOLOGY

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma

(2015) Siwen Hu-Lieskovan et al.   Science Translational Medicine

Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1

(2015) Zoran Gatalica et al.   Oncotarget

Potential clinical implications of BRAF mutations in histiocytic proliferations

(2015) Anna-Maria Bubolz et al.   Oncotarget

High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis

(2014) N. A. Brown et al.   BLOOD

BRAF-V600Eexpression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups

(2014) Marie-Luise Berres et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

BRAFV600E in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration

(2014) Trevor E. Angell et al.   THYROID

High expression of FOXP3 in primary melanoma is associated with tumour progression

(2013) A.L. Gerber et al.   BRITISH JOURNAL OF DERMATOLOGY

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis

(2012) F. Sahm et al.   BLOOD

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer

(2011) Lucia De Monte et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Recurrent BRAF mutations in Langerhans cell histiocytosis

(2010) G. Badalian-Very et al.   BLOOD

Tumors as Organs: Complex Tissues that Interface with the Entire Organism

(2010) Mikala Egeblad et al.   DEVELOPMENTAL CELL